Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.

Details

Ressource 1Download: PLoS ONE 2017 Spodzieja.pdf (3856.90 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_8C02B51C71F2
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Journal
PloS one
Author(s)
Spodzieja M., Lach S., Iwaszkiewicz J., Cesson V., Kalejta K., Olive D., Michielin O., Speiser D.E., Zoete V., Derré L., Rodziewicz-Motowidło S.
ISSN
1932-6203 (Electronic)
ISSN-L
1932-6203
Publication state
Published
Issued date
2017
Volume
12
Number
6
Pages
e0179201
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Antibody based immune-checkpoint blockade therapy is a major breakthrough in oncology, leading to clinical benefit for cancer patients. Among the growing family of inhibitory receptors, the B and T lymphocyte attenuator (BTLA), which interacts with herpes virus entry mediator (HVEM), is a promising target for immunotherapy. Indeed, BTLA inhibits T-cell proliferation and cytokine production. The crystal structure of the BTLA/HVEM complex has shown that the HVEM(26-38) fragment is directly involved in protein binding. We designed and analyzed the capacity of several analogs of this fragment to block the ligation between BTLA and HVEM, using competitive ELISA and cellular assay. We found that the HVEM(23-39) peptide can block BTLA/HVEM ligation. However, the blocking ability was due to the Cys encompassed in this peptide and that even free cysteine targeted the BTLA protein and blocked its interaction with HVEM. These data highlight a Cys-related artefact in vitro, which should be taken in consideration for future development of BTLA/HVEM blocking compounds.

Pubmed
Web of science
Open Access
Yes
Create date
28/06/2017 14:24
Last modification date
20/08/2019 15:50
Usage data